相关实验视频
Updated: Jun 21, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
阿司匹林和潘托普拉的固定剂量组合:印度患者的多中心,比较,随机,双盲,双人形,III期研究的结果
Rahul Choudhary1, Mohd Aziz Khan2, Rupal Dosi3
1Cardiology OPD 4 C-Block, AIIMS, Jodhpur, 342005, Rajasthan, India.
Indian heart journal
|July 15, 2024
概括
与单独使用阿司匹林相比,阿司匹林和潘托普拉的固定剂量组合显著减少了需要二次心血管预防的患者的胃肠道损伤. 这种组合提供了一种更安全,更有效的选择,用于预防胃肠道问题.
科学领域:
- 胃肠病学 胃肠病学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿司匹林对于心血管和脑血管疾病的二次预防至关重要.
- 阿司匹林的使用与胃肠粘膜损伤的风险增加有关.
- 质子抑制剂通常是共同处方以减轻这种风险.
研究的目的:
- 为了评估阿司匹林和潘托普拉的固定剂量组合的疗效和安全性.
- 将这种组合与单独的阿司匹林进行比较,以防止胃肠损伤.
- 评估需要长期服用阿司匹林治疗的患者的治疗结果,以进行二次预防.
主要方法:
- 一个比较的,双盲的,随机的,多中心的III期研究.
- 240名接受阿司匹林 (每天≤150毫克) 的患者被随机分组.
- 治疗组:固定剂量阿司匹林150毫克/潘托普拉20毫克与单独的阿司匹林150毫克24周.
主要成果:
- 固定剂量组合组在12周 (9.7%与19.7%) 和24周 (11.0%与22.4%) 显示出显著较低的非响应者比例 (胃肠关事件).
- 与对照组相比,在测试组观察到的胃肠道损伤明显减少.
- 这两种治疗方案都被所有参与者容忍得很好.
结论:
- 150毫克阿司匹林和20毫克潘托普拉的固定剂量组合比单独服用150毫克阿司匹林更有效.
- 这种组合提供了一个更安全的配置文件,以防止胃肠粘膜损伤.
- 它代表了对服用阿司匹林的患者进行二次预防的改进治疗选择.
相关概念视频
Peptic Ulcer Disease IV: Management
85
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
85
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
365
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
365
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
415
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
415
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
395
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
395
Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166

